Mouton Y, Leroy O, Beuscart C, Sivery B, Senneville E, Chidiac C, Beaucaire G, Vincent du Laurier M
Service Régional des Maladies Infectieuses, Centre Hospitalier de Tourcoing.
J Antimicrob Chemother. 1990 Nov;26 Suppl D:115-21. doi: 10.1093/jac/26.suppl_d.115.
The efficacy of intravenous ofloxacin therapy (200 mg 12-hourly) followed, when appropriate, by oral administration of the same dose was evaluated in an open multicentre trial involving 185 patients in 31 French hospitals. Dosage adjustment was made for patients in renal failure. Infection was hospital-acquired in 35 cases, 53 patients required admission to an intensive care unit. The infections comprised septicaemia (n = 56), pneumonia (n = 18), bronchitis (n = 10), urinary tract (n = 78), female pelvis (n = 8), bone and joint (n = 5), skin and soft tissues (n = 10). The causative pathogens were: Staphylococcus spp. (n = 23), Streptococcus spp. (n = 11), Escherichia coli (n = 85), Haemophilus influenzae (n = 9), Klebsiella, Enterobacter or Serratia spp. (n = 21), Salmonella spp. (n = 22), Chlamydia spp. (n = 3), Legionella spp. (n = 1), Mycoplasma pneumoniae (n = 1) and miscellaneous Gram-negative bacilli (n = 17). All were ofloxacin-susceptible. Mean duration of therapy was 8.06 ( +/- 2.6) days for the i.v. and 14.8 ( +/- 14.39) days for the oral preparation. Clinical cure was achieved in 173 patients (93.5%). It is concluded that iv ofloxacin is an effective treatment for a range of infections due to susceptible organisms.
在一项开放性多中心试验中，对31家法国医院的185例患者评估了静脉注射氧氟沙星疗法（每12小时200毫克）的疗效，必要时口服相同剂量的氧氟沙星。对肾衰竭患者进行了剂量调整。35例感染为医院获得性感染，53例患者需要入住重症监护病房。感染包括败血症（n = 56）、肺炎（n = 18）、支气管炎（n = 10）、泌尿系统感染（n = 78）、女性盆腔感染（n = 8）、骨和关节感染（n = 5）、皮肤和软组织感染（n = 10）。致病病原体为：葡萄球菌属（n = 23）、链球菌属（n = 11）、大肠杆菌（n = 85）、流感嗜血杆菌（n = 9）、克雷伯菌属、肠杆菌属或沙雷菌属（n = 21）、沙门菌属（n = 22）、衣原体属（n = 3）、军团菌属（n = 1）、肺炎支原体（n = 1）和其他革兰氏阴性杆菌（n = 17）。所有菌株对氧氟沙星均敏感。静脉注射治疗的平均疗程为8.06（±2.6）天，口服制剂为14.8（±14.39）天。173例患者（93.5%）实现了临床治愈。结论是，静脉注射氧氟沙星是治疗由敏感菌引起的一系列感染的有效方法。
